EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Muscle loss and GLP-1R agonists use

Giada Rossi, Loredana Bucciarelli, Chyrell-Lyn Mananguite, Matteo Giovarelli, Paolo Fiorina

Acta Diabetologica · 07.11.2025 · 63 (2) · 333-342

DOI: 10.1007/s00592-025-02611-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Diabetologica, online erschienen am 07.11.2025. Verfasst von Giada Rossi und 4 weiteren Autor:innen. Beteiligte Einrichtung: International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università degli Studi di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Sarcopenia, Hypoglycemic Agents. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero dell’Istruzione, dell’Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skeletal muscle wasting is a major yet often overlooked determinant of adverse outcomes in diabetes mellitus and obesity. Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, accelerates cardiometabolic decline and increases mortality risk. The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases particularly vulnerable to sarcopenia. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection. However, clinical trials and real-world evidence consistently show that weight reduction with GLP-1RAs is accompanied by decrease in lean body mass, raising concern in patients already predisposed to muscle wasting and underscoring the need for integrated management strategies. By including all English-language studies on muscle mass loss during GLP-1RA therapy in T2D and obesity from major scientific databases and clinical trial registries, this narrative review synthesizes the current knowledge on the epidemiology and mechanisms of muscle loss in diabetes and obesity, with a focus on the impact of GLP-1RAs therapy. It further examines preventive and therapeutic strategies to preserve muscle health during pharmacological weight loss, with the ultimate aim of providing clinicians and researchers with practical insights and future directions to maximize the benefits of GLP-1RAs while mitigating the risk of sarcopenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2SarcopeniaHypoglycemic AgentsMuscle, SkeletalHumansObesityWeight Loss

Stichwörter der Autor:innen

Diabetes mellitusGLP-1RAMuscle lossObesityPreventionTreatment

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università degli Studi di Milano, Milan, Italy.
  • Division of Endocrinology, ASST Fatebenefratelli Sacco, Milan, Italy.
  • Pio Albergo Trivulzio, Milan, Italy.
  • Internal Medicine Department, Clemenceau Hospital, Johns Hopkins International, Dubai, UAE.
  • Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Milan, Italy.
  • International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università degli Studi di Milano, Milan, Italy. paolo.fiorina@childrens.harvard.edu.

Förderung

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Ministero dell’Istruzione, dell’Università e della Ricerca

Zitieren

APA

Rossi, G., Bucciarelli, L., Mananguite, C. L., Giovarelli, M., & Fiorina, P. (2025). Muscle loss and GLP-1R agonists use. Acta Diabetologica, 63(2), 333-342. https://doi.org/10.1007/s00592-025-02611-2

Vancouver

Rossi G, Bucciarelli L, Mananguite CL, Giovarelli M, Fiorina P. Muscle loss and GLP-1R agonists use. Acta Diabetologica. 2025;63(2):333-342. doi:10.1007/s00592-025-02611-2

BibTeX
@article{Rossi2025,
  author = {Rossi, Giada and Bucciarelli, Loredana and Mananguite, Chyrell-Lyn and Giovarelli, Matteo and Fiorina, Paolo},
  title = {Muscle loss and GLP-1R agonists use},
  journal = {Acta Diabetologica},
  year = {2025},
  volume = {63},
  number = {2},
  pages = {333--342},
  doi = {10.1007/s00592-025-02611-2}
}
Kostenlos starten →